| Indicator | Current Period | Prior Year Period | YoY |
|---|---|---|---|
| Revenue | ¥345.7B | ¥301.0B | +14.8% |
| Operating Income | ¥22.9B | ¥22.2B | +3.2% |
| Equity-method Investment Income | - | - | - |
| Ordinary Income | ¥21.5B | ¥21.5B | +0.0% |
| Net Income | ¥14.2B | ¥12.8B | +10.6% |
| ROE | 4.9% | 4.7% | - |
2026 FY Q2 results: Revenue ¥345.7B (YoY +¥44.7B +14.8%), Operating Income ¥22.9B (YoY +¥0.7B +3.2%), Ordinary Income ¥21.5B (YoY ±¥0.0B +0.0%), Net Income ¥14.2B (YoY +¥1.4B +10.6%). Revenue growth supported operating and double-digit net profit increases, but gross margin contracted to 34.9% (from 36.2% YoY, -1.3pt) and operating margin declined to 6.6% (from 7.4% YoY, -0.8pt). By segment, Chemicals drove a sharp recovery with operating income +218.9%, while HBC & Food saw Revenue +41.3% but Operating Income -33.8% with margin deteriorating to 3.2%. Operating Cash Flow (OCF) improved to ¥25.7B (YoY +140.0%), Free Cash Flow (FCF) ¥11.0B, though inventory increase of -¥14.8B pressured cash flow. Leverage is high with Debt/EBITDA 5.63x, but short-term borrowings were compressed to ¥91.9B and long-term borrowings extended to ¥110.7B improving the maturity profile. Progress against full-year plan: Operating 67.5%, Ordinary 65.1%, Net Income 60.3% — above mid-year norms, suggesting upside potential.
[Revenue] Revenue ¥345.7B (+14.8%) increased. By segment, HBC & Food ¥114.0B (+41.3%) and Chemicals ¥59.9B (+33.1%) expanded strongly; Pharmaceuticals ¥64.2B (+4.2%) remained robust. Fine Chemicals declined to ¥113.7B (-4.3%). HBC benefited from new sales channels and expanded product lineup; Chemicals saw large gains from market recovery and higher demand. Fine Chemicals was impacted by demand weakness in some products. External customer sales ¥345.7B equals consolidated sales after intersegment eliminations.
[Profitability] Cost of sales ¥225.0B, gross profit ¥120.7B, gross margin 34.9% (from 36.2% YoY, -1.3pt). Selling, general and administrative expenses ¥97.8B (SG&A ratio 28.3%, from 28.8% YoY, -0.5pt) improved in efficiency, but gross margin decline led to Operating Income ¥22.9B (+3.2%) and operating margin 6.6% (-0.8pt). Segment Operating Income: Chemicals ¥6.1B (+218.9%, margin 10.1%), Pharmaceuticals ¥6.6B (-3.1%, margin 10.2%), Fine Chemicals ¥7.3B (-16.3%, margin 6.4%), HBC ¥3.6B (-33.8%, margin 3.2%). Chemicals’ rapid recovery supported group-level operating income, while HBC profit decline and gross margin deterioration were headwinds. Non-operating income ¥1.6B, non-operating expenses ¥3.1B (including interest expense ¥1.4B) for net -¥1.5B; Ordinary Income ¥21.5B (flat YoY). Extraordinary loss ¥0.1B (including impairment loss ¥1.2B) was temporary. Pre-tax income ¥21.4B, income taxes ¥7.3B (effective tax rate 34.0%), Net Income ¥14.2B (+10.6%). Comprehensive income ¥16.7B benefited from ¥1.1B translation adjustment and ¥1.9B valuation difference on available-for-sale securities. Conclusion: higher revenue and profit, but margin compression and weaker profitability in some segments pose qualitative issues.
Fine Chemicals: Revenue ¥113.7B (-4.3%), Operating Income ¥7.3B (-16.3%), margin 6.4%. Core business but lower revenue and profit due to demand slowdown for certain products. HBC & Food: Revenue ¥114.0B (+41.3%), Operating Income ¥3.6B (-33.8%), margin 3.2%. Large revenue increase from channel expansion, but margin fell sharply due to price competition and product-mix changes. Pharmaceuticals: Revenue ¥64.2B (+4.2%), Operating Income ¥6.6B (-3.1%), margin 10.2%. Stable earnings maintaining double-digit margins. Chemicals: Revenue ¥59.9B (+33.1%), Operating Income ¥6.1B (+218.9%), margin 10.1%. Rapid growth from market recovery and increased demand, with margin improvement driving group results. Others: Revenue ¥0.4B, Operating loss ¥1.3B. Overall, Chemicals and Pharmaceuticals form the profit core with double-digit margins; improving HBC profitability is the next priority.
[Profitability] ROE 4.9% is composed of Net Profit Margin 4.1% × Total Asset Turnover 0.462 × Financial Leverage 2.60. Operating margin 6.6% (prior 7.4%), gross margin 34.9% (prior 36.2%), SG&A ratio 28.3% (prior 28.8%). Gross margin decline is the main driver of margin compression, partially offset by SG&A efficiency. EBITDA ¥35.97B (adding depreciation ¥13.0B to Operating Income) yields EBITDA margin 10.4%. [Cash Quality] Operating CF ¥25.7B is 1.81x Net Income, indicating solid cash backing for earnings. OCF/EBITDA 0.71x shows weak cash conversion, with inventory increase -¥14.8B a constraining factor. Accrual ratio -1.5% is low, indicating high quality of earnings conversion to cash. Working capital: DSO 189 days, DIO 222 days, DPO 159 days, CCC 252 days indicating prolonged cash conversion cycle. [Investment Efficiency] ROIC 3.8% (NOPAT / invested capital) is below cost of capital. Total Asset Turnover 0.462 (Revenue ¥345.7B / Total Assets ¥748.6B) improved from 0.396. Capital expenditure ¥14.7B is 1.13x depreciation ¥13.0B, maintaining balance between maintenance and growth. [Financial Health] Equity Ratio 38.5%, Debt/Equity 0.70, interest-bearing debt ¥202.6B, Debt/EBITDA 5.63x. EBITDA interest coverage 24.98x (EBITDA ¥35.97B / interest paid ¥1.44B) indicates strong interest coverage. Current ratio 151%, Quick ratio 122% signifying healthy short-term liquidity.
Operating CF ¥25.7B (YoY +140.0%). Operating CF subtotal ¥32.3B less working capital increase -¥5.2B and tax payments -¥6.5B. Inventory increase -¥14.8B, decrease in trade receivables +¥4.9B, increase in trade payables +¥5.5B — inventory buildup pressured cash flow. Operating CF / Net Income 1.81x, OCF/EBITDA 0.71x, with cash conversion constrained by inventory. Investing CF -¥14.7B (CapEx -¥14.7B, intangible asset investment -¥0.7B, other -¥0.4B). FCF ¥11.0B (Operating CF ¥25.7B - CapEx ¥14.7B) providing capacity to cover dividend payments ¥3.7B. Financing CF -¥25.9B: net decrease in short-term borrowings -¥76.5B, long-term borrowings raised +¥68.0B, long-term borrowings repayments -¥13.3B, lease payments -¥0.4B, dividend payments -¥3.7B, treasury stock transactions ±¥0.0B. Shift from short-term to long-term borrowings improved maturity profile. Cash decreased to ¥86.4B (from ¥101.9B prior year, -¥15.5B).
Ordinary Income ¥21.5B comprises Operating Income ¥22.9B and net non-operating -¥1.5B, indicating core earnings are from operations. Non-operating income ¥1.6B (of which foreign exchange gains ¥0.3B, equity-method investment income ¥0.1B), non-operating expenses ¥3.1B (of which interest expense ¥1.4B, foreign exchange losses ¥0.3B) — limited financial volatility. Extraordinary items loss ¥0.1B (impairment loss ¥1.2B - gain on sale of fixed assets ¥0.0B) temporary. Pre-tax income ¥21.4B less income taxes ¥7.3B (effective tax rate 34.0%) yields Net Income ¥14.2B. Comprehensive income ¥16.7B adds translation adjustment ¥1.1B, valuation difference on securities ¥1.9B, retirement benefit adjustments -¥0.5B to Net Income. Accrual ratio -1.5% and Operating CF / Net Income 1.81x indicate strong cash backing and good earnings quality. OCF/EBITDA 0.71x driven by inventory accumulation; normalizing working capital is key to cash quality.
Full-year forecast: Revenue ¥680.0B (+8.4%), Operating Income ¥34.0B (+12.6%), Ordinary Income ¥33.0B (+13.3%), Net Income ¥23.5B. Progress at Q2: Revenue 50.8%, Operating 67.5%, Ordinary 65.1%, Net Income 60.3% — profit items are 10–17pt ahead of mid-year standard 50%. Chemicals’ rapid recovery, SG&A efficiency, and FX effects likely contributed. Downside/upside: second half could see further upside if inventory adjustments and HBC margin improvements proceed, but sustained gross margin decline or market volatility are risks. Dividend forecast annual ¥9 (payout ratio 38.3%), with sufficient FCF coverage. No revisions to forecasts; likelihood of achieving plan is high.
Interim dividend ¥9 (payout ratio 26.2%), sustainability is high. FCF coverage 2.96x (FCF ¥11.0B / dividend ¥3.7B), Operating CF to dividend ratio 6.95x, indicating ample dividend capacity. Interim dividend maintained at ¥9 YoY. Full-year forecast dividend ¥9 (payout ratio 38.3% based on full-year Net Income ¥23.5B) consistent with historical practice. No share buyback disclosed; shareholder returns focus on dividends. Total Return Ratio equals payout ratio. Despite high leverage, maintained dividends and improved cash generation raised CF coverage vs. prior year. Dividend policy is stability-oriented; improving working capital efficiency and longer-term borrowings are prerequisites for expanding return capacity.
Risk of HBC & Food margin deterioration becoming structural: Operating Income ¥3.6B (margin 3.2%, prior year ¥5.4B margin 6.8%) shows clear profitability deterioration. Revenue grew +41.3% but Operating Income fell -33.8%, reflecting price competition and product-mix changes as structural issues. This is a main cause of group gross margin 34.9% (-1.3pt); HBC margin recovery is key to restoring group operating margin. Quantitative impact approx -¥1.8B (change in Operating Income YoY).
Risk of CF pressure from deteriorating working capital efficiency: Inventory ¥87.5B (from ¥80.4B prior year, +8.8%), DIO 222 days, DSO 189 days, CCC 252 days indicating prolonged inventory/receivables. Inventory increase -¥14.8B pressured Operating CF and OCF/EBITDA 0.71x constrains cash conversion. Continued working capital expansion with revenue growth could dampen FCF generation and reduce financial flexibility. Quantitative impact approx -¥14.8B on Operating CF (inventory increase).
High leverage and refinancing risk: Interest-bearing debt ¥202.6B, Debt/EBITDA 5.63x, short-term debt ratio 45.4% (short-term borrowings ¥91.9B + current liabilities ¥305.9B). Short-term borrowings compressed from ¥161.9B to ¥91.9B and long-term borrowings extended to ¥110.7B, but short-term liabilities remain sizable. EBITDA interest coverage 24.98x shows strong interest resilience, but if interest rates rise or EBITDA contracts, covenant pressures may emerge. Quantitative impact is upward pressure on interest payments amounting to ¥1.4B.
Profitability & Returns
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Margin | 6.6% | – | – |
| Net Profit Margin | 4.1% | 7.0% (6.4%–7.5%) | -2.9pt |
Net Profit Margin is 2.9pt below industry median, placing profitability in the lower range. Gross margin decline and low HBC margins are main drivers.
Growth & Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth (YoY) | 14.8% | 4.5% (2.2%–5.8%) | +10.4pt |
Revenue growth outperforms industry median by 10.4pt, with Chemicals and HBC contributing to top-line strength.
※ Source: Company compilation
Profit progress front-loading and Chemicals recovery: Operating progress 67.5% and Net Income progress 60.3% vs. full-year plan exceed mid-year standard by +10–17pt, driven by Chemicals Operating Income +218.9%. Second-half upside exists depending on inventory adjustments and market trends; maintaining high margins in Chemicals and Pharmaceuticals is key to improving group ROE.
Priority on improving working capital efficiency: Inventory increase -¥14.8B and CCC 252 days make cash conversion a challenge. Although Operating CF ¥25.7B (+140.0%) improved, OCF/EBITDA 0.71x is below industry norm. Progress in reducing inventory and receivables is crucial for sustainable FCF and capital efficiency; monitoring DSO and DIO shortening is recommended.
Extending debt maturity and margin recovery: Shifting from short-term to long-term borrowings improved maturity profile. Debt/EBITDA 5.63x remains high, but interest coverage 24.98x provides near-term resilience. Continued risk of gross margin decline (34.9%, -1.3pt) means HBC margin recovery and maintaining Chemicals spreads are conditions for restoring group margins.
This report was automatically generated by AI analyzing XBRL financial statement data. It does not constitute a recommendation to invest in any specific security. Industry benchmarks are reference information compiled by the Company based on public financial statements. Investment decisions are your responsibility; consult a professional advisor as appropriate.